1. What Is the Biologics CDMO Market?
The Biologics CDMO Market covers the contract development and manufacturing organisations that provide outsourced biologics development, process development, and commercial manufacturing services to pharmaceutical and biotech companies, supplied across all stages from early-stage cell line development to commercial biologic production. Pharmaceutical and biotech companies use biologics CDMOs to access manufacturing capacity, process expertise, and regulatory capabilities without building in-house biologic production facilities. The market serves monoclonal antibody, recombinant protein, gene therapy, cell therapy, and vaccine manufacturing, with complex biologic manufacturing requiring large capital investment and specialised knowledge that CDMOs amortise across multiple clients. It includes upstream fermentation and cell culture, downstream purification, analytical testing, and formulation and fill-finish, with demand driven by the expanding biologic pipeline and the capital efficiency of outsourcing.
2. Biologics CDMO Market Size & Forecast
3. Emerging Technologies
- Mammalian cell culture bioreactor suites producing monoclonal antibodies and recombinant proteins for CDMO clients.
- Gene therapy viral vector manufacturing including AAV and lentiviral production for the growing cell and gene therapy pipeline.
- Single-use bioreactor facilities enabling rapid campaign changeover for multi-client flexible capacity.
- Formulation and aseptic fill-finish for injectable biologics completing the manufacturing value chain at the CDMO.
Such innovations are driving change across adjacent industries too. Discover more in our Cell Culture Media Market.
4. Key Market Opportunity
The largest near-term opportunity in the Biologics CDMO market lies in biotech companies without manufacturing capability outsourcing clinical and commercial biologic production to CDMOs. A second, faster-growing opportunity lies in pharmaceutical companies using CDMOs for overflow capacity and supply chain resilience alongside in-house production. As adoption broadens, the addressable opportunity is expanding from early deployments toward wider commercial use, with Europe positioned for the most rapid growth through 2034.
5. Top Companies in the Biologics CDMO Market
The following organisations hold leading positions in the Biologics CDMO Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Samsung Biologics
- Lonza
- Fujifilm Diosynth
- Wuxi Biologics
- Catalent (Novo Holdings)
- Oxford Biomedica
- Thermo Fisher Scientific (Brammer Bio)
- AGC Biologics
- Boehringer Ingelheim Biopharmaceuticals
- Rentschler Biopharma
6. Market Segmentation
The Biologics CDMO Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Service | Upstream Cell Culture Downstream Purification Analytical Testing Fill-Finish |
| By Molecule Type | Monoclonal Antibody Recombinant Protein Gene Therapy Vector Cell Therapy |
| By Scale | Clinical Commercial |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Biologics CDMO Market trajectory over the forecast period:
Samsung Biologics Has Built the World's Largest Single-Site Biologic Manufacturing Campus in Incheon.Samsung Biologics has built the world's largest single-site biologic manufacturing campus in Incheon, South Korea, with capacity across multiple large-scale bioreactor facilities serving global pharmaceutical clients. Lonza, the Swiss CDMO, and Fujifilm Diosynth Biotechnologies compete for mammalian cell culture and microbial manufacturing capacity. The post-pandemic contraction in mRNA vaccine manufacturing capacity released some CDMO investment toward conventional biologic services. Wuxi Biologics in China serves global pharma from Asian manufacturing. The concentration of capacity investment at a small number of very large players distinguishes the biologics CDMO from the fragmented small-molecule CDMO market.
Gene and Cell Therapy Manufacturing Has Become a Distinct High-Growth Segment.Gene and cell therapy manufacturing has become a distinct high-growth segment within biologics CDMO, as viral vector and CAR-T manufacturing requires specialised expertise and clean-room capacity that is in short supply. Oxford Biomedica, Brammer Bio (Thermo Fisher), and Lonza have invested in viral vector capacity. The demand for gene therapy manufacturing is growing with the pipeline of approved and late-stage products. This complex manufacturing segment commands premium pricing.
Single-Use Bioreactor Technology Has Enabled More Flexible CDMO Capacity.Single-use bioreactor technology has enabled more flexible CDMO capacity, as disposable systems avoid cleaning validation and allow faster turnaround between client campaigns. The adoption of single-use is near-universal in CDMO facilities for clinical and moderate commercial scale.
For related market intelligence, see the Single USe Bioreactor Market.
8. Segmental Analysis
By service, the upstream cell culture segment dominated the Biologics CDMO Market in 2025, as bioreactor-based protein and antibody production represents the largest CDMO service category.
By molecule type, the gene therapy vector segment is projected to register the highest CAGR in the Biologics CDMO Market through 2034, as viral vector manufacturing demand grows with the gene therapy approval pipeline, driving the fastest-growing molecule type category within the market.
9. Regional Analysis
Regional demand patterns across the Biologics CDMO Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Biologics CDMO Market in 2025, accounting for the largest share of revenue. Moreover, the United States hosts the most advanced gene and cell therapy CDMO services and the largest concentration of biotech clients outsourcing clinical-stage biologic manufacturing. In addition, Thermo Fisher, Catalent, and AGC Biologics serve US clients from domestic facilities. Premium gene therapy manufacturing pricing and clinical stage demand anchor revenue leadership.
Highest CAGR Region
Europe is projected to register the highest CAGR in the Biologics CDMO Market through 2034. The primary driver is European pharmaceutical investment in CDMO capacity for biologic manufacturing as biosimilar and novel biologic pipelines grow, combined with gene therapy viral vector capacity expansion by Oxford Biomedica, Lonza Switzerland, and Fujifilm Diosynth. Moreover, EU regulatory alignment and the proximity of European CDMOs to pharma clients drive outsourcing expansion. The combination of these demand drivers and an expanding base positions Europe for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Biologics CDMO Market was valued at USD 18.47 Bn in 2025 and is projected to reach USD 63.98 Bn by 2034, growing at a CAGR of 14.8% over the 2026–2034 forecast period.
The Biologics CDMO Market is projected to grow at a CAGR of 14.8% from 2026 to 2034.
North America dominated the Biologics CDMO Market in 2025, accounting for the largest share of revenue.
The leading companies in the Biologics CDMO Market include Samsung Biologics, Lonza, Fujifilm Diosynth, Wuxi Biologics, Catalent (Novo Holdings), Oxford Biomedica, Thermo Fisher Scientific (Brammer Bio), AGC Biologics, Boehringer Ingelheim Biopharmaceuticals, Rentschler Biopharma.
Samsung biologics has built the world's largest single-site biologic manufacturing campus in incheon.
By service, the upstream cell culture segment dominated the Biologics CDMO Market in 2025, as bioreactor-based protein and antibody production represents the largest CDMO service category.
How to Order
Choose Your Package
Condensed edition of this study for students, researchers and academic institutions.
- Condensed edition of the full study
- For students, researchers & academic institutions
- Valid student ID or institutional email required
- Educational, non-commercial use only
The competitive landscape, including key market participants, company size, market positioning, and comparative competitive standing.
- 15 in-depth company profiles
- Company overview
- Product and brand portfolio mapped per company
- Revenue for the last 3 FYs with key financial metrics
- Segmental revenue and regional revenue breakdown
- Market presence, key geographies & end-use industries
- Recent developments
- Key capabilities, differentiators & strategic positioning
- SWOT Analysis
- 15-company market share analysis
- 2025 market share by company
- Company revenue in USD
- Competitive quadrant positioning
- Product portfolio comparison
The complete forecast model, including every study table, is provided in clean, formula-ready Excel format across 3 segmentation axes. Select the geographic coverage required for your analysis.
- One country, broken out across 3 segmentation axes
- 2025 base year, 2026–2034 forecast, CAGR per line
- Excel workbook
- Region totals plus every country inside that region
- All axes, all years, CAGR per line
- Cross-country comparison sheet included
- Excel workbook
- Every forecast table in the study
- Global, regional and country views in one workbook
- Segment share and CAGR pivots included
- Excel workbook
The full syndicated study. Every chapter, every region, every country, plus the complete Excel model, methodology and appendix.
- Executive summary, market scope & segmental snapshot
- Market dynamics: drivers, restraints, opportunities, challenges
- Quantitative analysis across 3 segmentation axes
- Regional analysis
- Competitive landscape, market share & company revenue mapping
- Includes the full Global Excel Data Pack
- Complete research methodology, assumptions & appendix
TAM/SAM/SOM sizing, M&A target screening, patent & IP analysis, supply-chain resilience mapping, ESG roadmaps and other bespoke strategic work.
- TAM / SAM / SOM sizing
- M&A target screening
- Patent & IP analysis
- Supply-chain resilience mapping
- ESG roadmaps & other bespoke strategic work
Not sure which package fits? Tell us the decision you are making and an analyst will recommend the smallest package that answers it. Talk to an analyst.
Ordering Process
Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.